Advisory Board
Many years of dedicated work in the pharmaceutical industry build the foundations of our advisory board, with significant expertise in drug development and commercialisation for hematological diseases.
Advisory Board
Christoph Bucher
Head of Clinical Advisory Board
and Founder
Simone Seiter
Head of Commericial, Chair of Scientific Advisory Board, and Founder
Christoph Bucher
HEAD OF CLINICAL ADVISORY BOARD AND FOUNDER
Christoph is the CMO of Anaveon. Before, Christoph was at Roche, where he led the transition to the late-stage development of Crovalimab, a complement C5 inhibitor. Before that, Christoph was at the Novartis Institutes for BioMedical Research, where he led programs in the stem cell transplant and complement system spaces and conducted trials in cell therapy. He obtained his medical degree and training in stem cell transplantation and internal medicine in Basel, and he completed his postdoc in the immunobiology of graft-versus-host and graft-versus-leukemia effects in Bruce Blazar’s group at the University of Minnesota. Christoph continues to practice hematology part-time at the University Hospital Basel.
Simone Seiter
Head of Commericial, Chair of Scientific Advisory Board, and Founder
Simone is a Partner at Simon-Kucher & Partners, leading their Commercial Strategy Cluster within the Life Sciences division. Before joining the company, she was the global lead of IQVIA’s Brand & Commercial Strategy Team and lead their launch excellence platform. She is a board certified dermatologist and worked at the University hospitals in Heidelberg and Homburg in Germany, as well as at several dermatology clinics. She also worked as a postdoctoral fellow at the NIH. Simone specializes in strategic pharmaceutical commercialization, launch, and brand excellence, portfolio and lifecycle management, including go-to-market strategies, P&MA strategies, product lifecycle strategies, and orphan diseases. She has supported many of the current top 20 pharma companies in successfully developing and commercializing their healthcare innovations in Europe and the US. Simone has published a number of articles and white papers on launch excellence and coauthored the IQVIA Launch Excellence series.
“Drug appears to possibly impact GvL, what Priothera is doing is hugely relevant for patients and the media community.”
Prof. M. De Lima, USA – Director of the Blood and Bone Marrow Transplant and Cellular Therapy Program at the OSUCCC. A professor in the division of Hematology at the Ohio State University College of Medicine
“Mocravimod is a promising new treatment approach for maintenance in this setting of AML patients due to it’s double effect and potential to enhance GvL while suppressing GvHD.”
Prof. M. Mohty, Paris, FR – Former president of the European Society for Blood and Marrow Transplantation (EBMT), founder and chairman of the International Academy for Clinical Haematology